Lenvima Indications/Uses

Differentiated Thyroid Cancer (DTC): LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
Renal Cell Carcinoma (RCC): LENVIMA, in combination with pembrolizumab, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
LENVIMA is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
Hepatocellular Carcinoma (HCC): LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Endometrial Carcinoma (EC): LENVIMA, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation.